Synopsis: With a debt-free balance sheet and steady cash flows, Windlas Biotech Limited has informed exchanges that its board will meet on April 17, 2026, to consider an equity share buyback. This potential move marks a significant capital return event for the pharma CDMO.
Windlas Biotech Limited surged into the spotlight on April 14, 2026, after a regulatory filing revealed that its Board of Directors will convene this Friday, April 17, to evaluate a share buyback proposal.
While specific details regarding the buyback size, offer price, and execution method whether via tender offer or open market remain under wraps until the board’s final deliberation, the market has reacted with high optimism.
As of April 15, Windlas Biotech (WINDLAS) witnessed a sharp 6.10% rally in early trade on April 15, 2026, significantly outperforming the broader NIFTY 50’s 1.46% gain. After a strong opening at Rs. 855.00, the stock hit an intraday high of Rs. 875.00, supported by robust buying sentiment as indicated by the 51.80% buy-side order book.
The move marks a notable recovery from its recent 52-week low of Rs. 697.40 (hit in March 2026), with the stock now trading near its Volume Weighted Average Price (VWAP) of Rs. 863.20. This 19.42% surge over the last month suggests a bullish reversal in the pharma counter, even as it remains approximately 24% below its 52-week high of Rs. 1,140.00.
The buyback is backed by a debt-light balance sheet and robust liquidity, with Rs. 246 crore in investments and Rs. 524 crore in reserves against minimal borrowings. Fiscal strength is further supported by a Rs. 868 crore TTM revenue run-rate and Rs. 68 crore in FY25 operating cash flow. While the current valuation sits at roughly 3.1x book value, consistent internal accruals make this capital return sustainable without compromising the company’s growth trajectory.
Business Overview
Incorporated in 2001, Windlas Biotech Limited is a top-five domestic pharmaceutical formulation CDMO. It provides end-to-end services ranging from product discovery to the commercial manufacturing of complex generics. For the December 2025 quarter (Q3 FY26), the company reported consolidated revenue of Rs. 233 crore and a net profit of Rs. 15 crore.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Windlas Biotech Jumps 6% as Board Set to Consider Buyback on April 17 appeared first on Trade Brains.